---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-26-000005"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:55:57.929605+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GeneDx prelim FY2025 rev $427M (+41%); FY2026 guidance $540-555M

## Summary
- FY2025 exome/genome revenue ~$360M (+54% YoY); Q4 $104M (+32% YoY).
- Exome/genome volume 97,271 (+30.5%) for FY2025; Q4 volume up 34.3%.
- Adjusted gross margin 71% in Q4 and FY2025; cash & equivalents $172M.
- FY2026 guidance: rev $540-555M, 33-35% exome/genome growth, adj gross margin ≥70%.
- Expects positive adjusted net income in FY2026.

## SEC filing metadata
- accession: 0001818331-26-000005
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/0001818331-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833126000005/wgs-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-26-000005
- JSON: https://secwatch.observer/filing/0001818331-26-000005.json
- Plain text: https://secwatch.observer/filing/0001818331-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.